IP Library › Granted Patent US 7,635,479
Granted Patent B2
US 7,635,479 · App. 10/239,703 · Granted Dec 22, 2009

Composition and methods for enhancing immunogenecity of antigens

Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,635,479
App. No.
10/239,703
Granted
Dec 22, 2009
Kind
B2
Abstract

Compositions and methods for enhancing the immunogenicity of an antigen via fusion to a non-hemolytic truncated form of listeriolysin or a PEST-like amino acid sequence derived from a prokaryotic organism are provided.

Claims (35)

1. A composition with enhanced cell-mediated immunity and anti-tumor immunity comprising a fusion protein consisting of a PEST-like amino acid sequence selected from the group consisting of SEQ ID NOs: 1-7 fused to or embedded within an antigen.

2. The composition of claim 1 , wherein said PEST-like amino acid sequence consists of SEQ ID No: 1.

3. The composition of claim 1 , further comprising an adjuvant.

4. A method of retarding tumor growth in a subject, comprising administering to said subject a composition comprising a fusion protein consisting of a PEST-like amino acid sequence selected from the group consisting of SEQ ID NOs: 1-7 fused to or embedded within an antigen associated with said tumor.

5. The method of claim 4 , therein said PEST-like amino acid sequence is from a listeriolysin (LLO) protein.

6. The method of claim 4 , wherein said PEST-like amino acid sequence is from an ActA protein.

7. The method of claim 4 , wherein said PEST-like amino acid sequence is from a Streptolysin protein.

8. The method of claim 4 , wherein said PEST-like amino acid sequence consists of SEQ ID No: 1.

9. The method of claim 4 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 2-5.

10. The method of claim 4 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 6-7.

11. A method of inducing the regression of a tumor in a subject, comprising administering to said subject a composition comprising a fusion protein consisting of a PEST-like amino acid sequence selected from the group consisting of SEQ ID NOs: 1-7 fused to or embedded within an antigen associated with said tumor.

12. The method of claim 11 , wherein said PEST-like amino acid sequence is from a listeriolysin (LLO) protein.

13. The method of claim 11 , wherein said PEST-like amino acid sequence is from an ActA protein.

14. The method of claim 11 , wherein said PEST-like amino acid sequence is from a Streptolysin protein.

15. The method of claim 11 , wherein said PEST-like amino acid sequence consists of SEQ ID No: 1.

16. The method of claim 11 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 2-5.

17. The method of claim 11 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 6-7.

18. The composition of claim 1 , wherein said PEST-like amino acid sequence is from an ActA protein.

19. The composition of claim 1 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 2-5.

20. The composition of claim 1 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 6-7.

21. A method for enhancing the cell-mediated immunity of an antigen in a subject, comprising administering to said subject a composition comprising a fusion protein consisting of a PEST-like amino acid sequence selected from the group consisting of SEQ ID NOs: 1-7 fused to or embedded within said antigen.

22. The method of claim 21 , wherein said PEST-like amino acid sequence is from a listeriolysin (LLO) protein.

23. The method of claim 21 , wherein said PEST-like amino acid sequence is from an ActA protein.

24. The method of claim 21 , herein said PEST-like amino acid sequence is from a Streptolysin protein.

25. The method of claim 21 , wherein said PEST-like amino acid sequence consists of SEQ ID No: 1.

26. The method of claim 21 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 2-5.

27. The method of claim 21 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 6-7.

28. A method for invoking an enhanced cell-mediated or anti-tumor immunogenic response to an antigen in a subject, comprising administering to said subject a composition comprising a fusion protein consisting of a PEST-like amino acid sequence selected from the group consisting of SEQ ID NOs: 1-7 fused to or embedded within said antigen.

29. The method of claim 28 , wherein said PEST-like amino acid sequence is from a listeriolysin (LLO) protein.

30. The method of claim 28 , wherein said PEST-like amino acid sequence is from an ActA protein.

31. The method of claim 28 , wherein said PEST-like amino acid sequence is from a Streptolysin protein.

32. The method of claim 28 , wherein said PEST-like amino acid sequence consists of SEQ ID No: 1.

33. The method of claim 28 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 2-5.

34. The method of claim 28 , wherein said PEST-like amino acid sequence is selected from the group consisting of SEQ ID Nos: 6-7.

35. The composition of claim 1 , wherein said PEST-like amino acid sequence is from a listeriolysin (LLO) protein.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 14, 2013
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029992/0966 →
Continuity (1)
Related Publication 20070003567A1 · Jan 4, 2007